Skip to main content

Table 1 Characteristics of screened patients and HER2amp CTC detection

From: Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

Patients characteristics

Included pts.

(N = 154)

N (%)

Pts. with ≥1CTC

(N = 118)

N (%)

Pts. with ≥1CTC and interpretable FISHc

(N =79)

N (%)

Pts. with ≥ 1 HER2amp CTC

(N = 14)

N (%)

Age at inclusion

 ≤ 50 years

26 (17.0%)

18 (15.4%)

12 (15.2%)

3 (21.4%)

 > 50 years

127 (83.0%)

99 (84.6%)

67 (84.8%)

11 (78.6%)

 NA

1

1

  

Performance status

 PS 0

63 (44.4%)

40 (37.4%)

25 (33.8%)

3 (21.4%)

 PS 1

78 (54.9%)

66 (61.7%)

48 (64.9%)

10 (71.4%)

 PS 2

1 (0.7%)

1 (0.9%)

1 (1.4%)

1 (7.1%)

 NA

12

11

5

 

Tumor type

 NST

135 (89.4%)

103 (88.8%)

67 (85.9%)

13 (92.9%)

 Lobular

13 (8.6%)

10 (8.6%)

10 (12.8%)

1 (7.1%)

 Other

3 (2.0%)

3 (2.6%)

1 (1.3%)

0 (0%)

 NA

3

2

1

 

Tumor grade

 Grade I

10 (7.4%)

9 (8.7%)

7 (9.9%)

2 (16.7%)

 Grade II

80 (59.3%)

60 (58.3%)

44 (62.0%)

6 (50.0%)

 Grade III

45 (33.3%)

34 (33.0%)

20 (28.2%)

4 (33.3%)

 NA

19

15

8

2

Receptor status on primary tumor a

 ER− PR− HER2−

15 (10.1%)

10 (8.9%)

6 (8.1%)

0 (0%)

 ER+ and/or PR+, HER2−

125 (84.5%)

98 (87.5%)

67 (90.5%)

12 (100%)

 Not done

8 (5.4%)

4 (3.6%)

1 (1.4%)

0 (0%)

 NA

6

6

5

2

Receptor status on local/distant relapsea

 ER− PR− HER2−

17 (19.3%)

10 (15.4%)

8 (19.5%)

 

 ER+ and/or PR+, HER2−

63 (71.6%)

49 (75.4%)

30 (73.2%)

7 (87.5%)

 Not done

8 (9.1%)

6 (9.2%)

3 (7.3%)

1 (12.5%)

 NA

66

53

38

6

Number of prior lines of chemotherapyb

 2

65 (42.8%)

46 (39.7%)

33 (42.3%)

3 (21.4%)

 3

42 (27.6%)

34 (29.3%)

20 (25.6%)

4 (28.6%)

 ≥ 4

45 (29.6%)

36 (31.0%)

25 (32.1%)

7 (50.0%)

 NA

2

2

1

 

Number of CTC detected

 Screening CTC = 0

32 (21.3%)

   

 Screening CTC [1–4]

32 (21.3%)

32 (27.1%)

11 (13.9%)

0 (0%)

 Screening CTC ≥ 5

86 (57.3%)

86 (72.9%)

68 (86.1%)

14 (100%)

 NA

4

   
  1. NST invasive carcinoma of no special type, ER estrogen receptor, PR progesterone receptor
  2. aOne patient with a history of HER2-positive primary tumor was excluded and is not shown in this table
  3. bChemotherapies administered for metastatic disease
  4. cInterpretable FISH results: at least 1 CTC with both HER2 and CEP17 signals observed, with negative internal controls